机构地区:[1]安康市中医医院,陕西安康725000 [2]中国人民解放军第四军医大学,陕西西安710032
出 处:《临床医学研究与实践》2022年第10期28-31,共4页Clinical Research and Practice
基 金:国家自然科学基金委员会资助项目(No.81770345)。
摘 要:目的 探讨达比加群酯治疗心肌梗死的效果,以为临床该病的治疗提供参考。方法 选取2018年1月1日至2020年12月31日安康市中医医院收治的40例心肌梗死患者作为研究对象,以抽签法将其随机分为对照组和观察组,各20例。对照组给予常规治疗(阿司匹林肠溶胶囊、阿托伐他汀钙片、盐酸曲美他嗪片、注射用尿激酶),观察组在对照组基础上给予达比加群酯治疗。比较两组的临床疗效、凝血功能指标、炎症因子水平、不良反应发生情况。结果 观察组的治疗总有效率为95.00%,高于对照组的70.00%,差异具有统计学意义(P<0.05)。治疗前,两组的凝血酶原时间(PT)、凝血酶时间(TT)、活化部分凝血活酶时间(APTT)及纤维蛋白原(FIB)水平比较,差异无统计学意义(P>0.05);治疗后,两组的PT、TT、APTT均长于治疗前,FIB水平均低于治疗前,且观察组优于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的单核细胞趋化蛋白-1(MCP-1)、Toll样受体4(TLR4)、超敏C反应蛋白(hs-CRP)水平比较,差异无统计学意义(P>0.05);治疗后,两组的MCP-1、TLR4、hs-CRP水平均低于治疗前,且观察组低于对照组,差异具有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 达比加群酯治疗心肌梗死的效果良好,可改善患者的凝血功能指标,降低炎症因子水平,安全性良好,值得临床推广和应用。Objective To investigate the effect of dabigatran etexilate on myocardial infarction, so as to provide reference for the clinical treatment of the disease. Methods A total of 40 patients with myocardial infarction treated in Ankang hospital of traditional Chinese medicine from January 1, 2018 to December 31, 2020 were selected and randomly divided into control group and observation group by drawing lots, with 20 cases in each group. The control group was given routine treatment(aspirin delayed-release capsules, atorvastatin calcium tablets, trimetazidine hydrochloride tablets,urokinase for injection), and the observation group was given dabigatran etexilate treatment on the basis of the control group. The clinical efficacy, coagulation function indexes, inflammatory factors levels and occurrence of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the observation group was95.00%, which was higher than 70.00% in the control group, and the difference was statistically significant(P <0.05).Before treatment, there were no significant differences in prothrombin time(PT), thrombin time(TT), activated partial thromboplastin time(APTT) and fibrinogen(FIB) level between the two groups(P>0.05);after treatment, PT, TT and APTT of the two groups were longer than those before treatment, FIB level was lower than that before treatment, those in the observation group were better than the control group, and the differences were statistically significant(P<0.05). Before treatment, there were no significant differences in the monocyte chemoattractant protein-1(MCP-1), toll like receptor 4(TLR4) and high-sensitivity C-reactive protein(hs-CRP) levels between the two groups(P>0.05);after treatment, the MCP-1, TLR4 and hs-CRP levels in the two groups were lower than those before treatment, those in the observation group were lower than the control group, and the differences were statistically significant(P <0.05). There was no significant difference in the total incidence of advers
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...